Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Underwriters were supportive of the U.S. Supreme Court’s recent decision that generic drug manufacturers are not liable for defectively designed drugs, and the ruling is not expected to impact price and availability of liability coverage, say insurance brokers.

According to a June 24 decision in Mutual Pharmaceutical Co. Inc. v Bartlett, generic drug manufactures are not liable for an individual’s claim that a defective design in the drug harmed them. The court reasoned that because federal regulation bars the manufacturer from deviating from the brand-name product, they are not liable for adverse results.

Want to continue reading?
Become a Free
PropertyCasualty360 Digital Reader.


  • All PropertyCasualty360.com news coverage, best practices, and in-depth analysis.
  • Educational webcasts, resources from industry leaders, and informative newsletters.
  • Other award-winning websites including BenefitsPRO.com and ThinkAdvisor.com.

Already have an account?

Dig Deeper


Join PropertyCasualty360

Don’t miss crucial news and insights you need to make informed decisions for your P&C insurance business. Join PropertyCasualty360.com now!

  • Unlimited access to PropertyCasualty360.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including BenefitsPRO.com, ThinkAdvisor.com and Law.com
  • Exclusive discounts on PropertyCasualty360, National Underwriter, Claims and ALM events

Already have an account? Sign In Now
Join PropertyCasualty360

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.